Mankind Pharma's Rs.13,630 Crore Deal to Buy Bharat Serums Gets CCI Approval—A Game-Changer for Indian Healthcare

Mankind Pharma has received approval from the Competition Commission of India (CCI) for a Rs 13,630 crore deal to acquire Bharat Serums & Vaccines. The acquisition is considered a game-changer for Indian healthcare, as it will significantly expand Mankind Pharma’s portfolio in biotechnology and vaccine development. This deal reflects the ongoing consolidation in India’s healthcare industry, where major players are seeking to diversify and scale operations. The acquisition is expected to enhance India's domestic vaccine production capacity and contribute to the country’s healthcare security.